Resonance Specialties Limited has fixed Tuesday, July 28, 2026, as the record date to determine member eligibility for a dividend of Re 1 per share. The dividend, equivalent to 10% of the face value of ₹10 each, is subject to approval at the company's ensuing 37th Annual General Meeting (AGM). If sanctioned, the payout will be made on or before August 28, 2026.

The company's 37th AGM is scheduled for Tuesday, August 4, 2026, at 12:30 p.m. via video conferencing. The meeting will be conducted in compliance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Members attending through video conferencing will be reckoned for the purpose of quorum under Section 103 of the Act.

The Notice of the AGM and the Financial Statements for the Financial Year 2025-26, along with the Board of Directors' and Auditors' reports, will be sent exclusively by email to members whose email addresses are registered with the company, the Registrar and Share Transfer Agent (RTA), or Depository Participants. These documents will also be available on the company's website, the BSE Limited website, and the National Securities Depository Limited (NSDL) website.

The company has provided an electronic voting facility for members to exercise their rights on the agenda items. E-voting services will be provided by NSDL, and members can also vote during the AGM. Members holding shares in physical mode must send an email to the company or the RTA with their registered Folio Number, email address, self-attested PAN card, address proof, contact number, and bank account details to receive annual reports and dividends.

Resonance Specialities Limited reported a net profit of ₹10.40 crore for the financial year ended March 31, 2026, a 58% increase from ₹6.57 crore in the previous year. Total income for the period rose 17% to ₹91.89 crore, compared to ₹78.79 crore in FY25, primarily driven by higher sales and export business in key products. The company’s earnings per share (EPS) improved to ₹9.01 from ₹5.69 in the previous year.

Financial Performance

The company’s profit before tax stood at ₹14.07 crore, up from ₹8.88 crore in the previous year. Profit before interest, depreciation, and taxation increased to ₹15.65 crore from ₹11.58 crore. The board has recommended an equity dividend of ₹1 per share (10%) for the financial year, amounting to ₹1.15 crore, which will be paid on or before August 28, 2026, if approved at the Annual General Meeting.

Operational Highlights

The financial performance improved due to increased sales and export business. The company’s exports, including deemed exports, were recorded at ₹53.55 crore, compared to ₹34.11 crore in the previous year. Resonance Specialities focuses on manufacturing pyridine and pyridine derivatives, picolines, and bulk drugs. The company continues to explore newer markets for its products.

Corporate Governance and Approvals

The board has approved the re-appointment of M/s. Kailash Chand Jain & Co., Chartered Accountants, as statutory auditors for a further period of five years. Additionally, the board has sought shareholder approval to enter into related party transactions with Kaygee Laboratories Private Limited up to a maximum aggregate value of ₹40 crore in any given financial year. The 37th Annual General Meeting is scheduled for August 4, 2026, via video conferencing.